他达拉非治疗勃起功能障碍。
Tadalafil in the treatment of erectile dysfunction.
机构信息
Division of Urologic Surgery, University of North Carolina, Chapel Hill, NC, USA.
出版信息
Ther Clin Risk Manag. 2008 Dec;4(6):1315-30. doi: 10.2147/tcrm.s3336.
Abstract
The treatment for erectile dysfunction (ED) was revolutionized with the development of phosphodiesterase type 5 (PDE5) inhibitors. Tadalafil (Cialis((R)); Eli Lilly and Company, Indianapolis, IN, USA) is the newest and most versatile PDE5 inhibitor in the clinical armamentarium for the treatment of ED. Its most unique characteristic is its long half-life of 17.5 hours, which lends itself to a longer therapeutic window with on-demand dosing and effective steady-state plasma concentrations with once-daily dosing. Clinical trials have proven its safety and efficacy with both dosing strategies for all severities and etiologies of ED, including difficult-to-treat ED. This thorough review will discuss ED, the physiology of penile erection and the role of PDE5, and all aspects of tadalafil, from its development, through its pharmacology, to its latest clinical studies and indications.
摘要
治疗勃起功能障碍 (ED) 的方法随着磷酸二酯酶 5 (PDE5) 抑制剂的发展而发生了革命性变化。他达拉非（商品名：希爱力((R)); Eli Lilly and Company, Indianapolis, IN, USA）是临床治疗 ED 的 PDE5 抑制剂中最新和用途最广泛的一种。它最独特的特点是半衰期长达 17.5 小时，这使得按需给药具有更长的治疗窗口，并且每日一次给药可达到有效的稳定状态血浆浓度。临床试验已经证明，对于所有严重程度和病因的 ED，包括难治性 ED，这两种给药方案都具有安全性和有效性。这篇全面的综述将讨论 ED、阴茎勃起的生理学以及 PDE5 的作用，以及他达拉非的各个方面，从它的开发到它的药理学，再到它最新的临床研究和适应症。
相似文献
1
Tadalafil in the treatment of erectile dysfunction.
Ther Clin Risk Manag. 2008 Dec;4(6):1315-30. doi: 10.2147/tcrm.s3336.
2
SOP conservative (medical and mechanical) treatment of erectile dysfunction.
J Sex Med. 2013 Jan;10(1):130-71. doi: 10.1111/jsm.12023.
3
[Chronic PDE-5 inhibition in patients with erectile dysfunction: new treatment approach using once daily Tadalafil].
Urologe A. 2009 Nov;48(11):1318, 1320-9. doi: 10.1007/s00120-009-2089-y.
4
PDE5 inhibitors: are there differences?
Can J Urol. 2006 Feb;13 Suppl 1:34-9.
5
A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapy.
J Sex Med. 2014 Mar;11(3):820-30. doi: 10.1111/jsm.12253. Epub 2013 Jul 10.
6
A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are naïve to PDE5 inhibitors.
J Sex Med. 2011 Sep;8(9):2617-24. doi: 10.1111/j.1743-6109.2011.02353.x. Epub 2011 Jun 27.
7
Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
Eur Urol. 2013 May;63(5):902-12. doi: 10.1016/j.eururo.2013.01.012. Epub 2013 Jan 31.
8
Review of tadalafil in the treatment of erectile dysfunction.
Expert Opin Pharmacother. 2003 Nov;4(11):2049-56. doi: 10.1517/14656566.4.11.2049.
9
Treatment satisfaction of men and partners following switch from on-demand phosphodiesterase type 5 inhibitor therapy to tadalafil 5 mg once daily.
J Sex Med. 2015 Mar;12(3):720-7. doi: 10.1111/jsm.12818. Epub 2015 Jan 23.
10
Tadalafil: 15 years' journey in male erectile dysfunction and beyond.
Drug Dev Res. 2018 Dec 13. doi: 10.1002/ddr.21493.
引用本文的文献
1
Tailored transethosomal systems for tadalafil transdermal delivery: Impact of Phosal and edge activators on skin permeation and cellular uptake.
Int J Pharm X. 2025 Aug 16;10:100376. doi: 10.1016/j.ijpx.2025.100376. eCollection 2025 Dec.
2
Tamsulosin plus Tadalafil compared with Tamsulosin alone for benign prostate hyperplasia in patients with or without erectile dysfunction: a meta-analysis and meta-regression of randomized controlled trials.
World J Urol. 2025 May 11;43(1):291. doi: 10.1007/s00345-025-05662-w.
3
Tadalafil pretreatment attenuates doxorubicin-induced hepatorenal toxicity by modulating oxidative stress and inflammation in Wistar rats.
Toxicol Rep. 2024 Sep 16;13:101737. doi: 10.1016/j.toxrep.2024.101737. eCollection 2024 Dec.
4
Effects of Postprandial Factors and Second Meal Intake Time on Bioequivalence Investigation of Tadalafil-Loaded Orodispersible Films in Human Volunteers.
Pharmaceutics. 2024 Jul 9;16(7):915. doi: 10.3390/pharmaceutics16070915.
5
Chemoreactive 2,5-Diketopiperazines from a sp., Structure Revision of Reported Analogues and Proposed Facile Transformation Pathways.
J Nat Prod. 2024 Jul 26;87(7):1826-1837. doi: 10.1021/acs.jnatprod.4c00478. Epub 2024 Jul 12.
6
Cyclodipeptide oxidase is an enzyme filament.
Nat Commun. 2024 Apr 27;15(1):3574. doi: 10.1038/s41467-024-48030-9.
7
Evaluation of efficacy and safety profile of tadalafil 5 mg daily dose in the tablet form versus oral dispersible film in men with mild-to-moderate erectile dysfunction: a comparative placebo-controlled study.
Int Urol Nephrol. 2024 Aug;56(8):2531-2537. doi: 10.1007/s11255-024-04003-x. Epub 2024 Mar 4.
8
Food Administration and Not Genetic Variants Causes Pharmacokinetic Variability of Tadalafil and Finasteride.
J Pers Med. 2023 Oct 31;13(11):1566. doi: 10.3390/jpm13111566.
9
In Vitro Drug Repurposing: Focus on Vasodilators.
Cells. 2023 Feb 20;12(4):671. doi: 10.3390/cells12040671.
10
Boosting Tadalafil Bioavailability via Sono-Assisted Nano-Emulsion-Based Oral Jellies: Box-Behnken Optimization and Assessment.
Pharmaceutics. 2022 Nov 24;14(12):2592. doi: 10.3390/pharmaceutics14122592.
本文引用的文献
1
Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study.
J Urol. 2008 Oct;180(4):1228-34. doi: 10.1016/j.juro.2008.06.079. Epub 2008 Aug 22.
2
Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy.
Int J Impot Res. 2008 Sep-Oct;20(5):479-86. doi: 10.1038/ijir.2008.33. Epub 2008 Jul 24.
3
Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy.
Eur Urol. 2008 Oct;54(4):924-31. doi: 10.1016/j.eururo.2008.06.083. Epub 2008 Jul 9.
4
Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction.
J Sex Med. 2008 Sep;5(9):2160-9. doi: 10.1111/j.1743-6109.2008.00935.x. Epub 2008 Jun 28.
5
Epidemiology and pathophysiology of male sexual dysfunction.
Int J Impot Res. 2008 Jul;20 Suppl 1:S3-10. doi: 10.1038/ijir.2008.16.
6
5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study.
J Urol. 2008 May;179(5 Suppl):S40-4. doi: 10.1016/j.juro.2008.03.136.
7
National Hospital Discharge Survey: 2005 annual summary with detailed diagnosis and procedure data.
Vital Health Stat 13. 2007 Dec(165):1-209.
8
Investigating women's preference for sildenafil or tadalafil use by their partners with erectile dysfunction: the partners' preference study.
J Sex Med. 2008 May;5(5):1198-1207. doi: 10.1111/j.1743-6109.2008.00774.x. Epub 2008 Feb 25.
9
Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction.
Diabet Med. 2008 Feb;25(2):138-46. doi: 10.1111/j.1464-5491.2007.02338.x.
10
Tadalafil (Cialis) and erectile dysfunction after radiotherapy for prostate cancer: an open-label extension of a blinded trial.
Urology. 2007 Dec;70(6):1190-3. doi: 10.1016/j.urology.2007.08.029.
Zotero 插件